Project Affinity: Excess Cancer Blood Testing
Sponsor
Entia Ltd (Industry)
Overall Status
Active, not recruiting
CT.gov ID
NCT04724005
Collaborator
(none)
600
1
12.5
47.9
Study Details
Study Description
Brief Summary
Study investigating cancer blood samples on an iterative measurement systme
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Study Design
Study Type:
Observational
Anticipated Enrollment
:
600 participants
Observational Model:
Other
Time Perspective:
Retrospective
Official Title:
Project Affinity: Excess Cancer Blood Testing Technique
Actual Study Start Date
:
Apr 15, 2021
Anticipated Primary Completion Date
:
May 1, 2022
Anticipated Study Completion Date
:
May 1, 2022
Outcome Measures
Primary Outcome Measures
- Viability of measurement technique [12 months]
Viability of measurement technique
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
-
Undergoing SACT
-
Routine blood tests
Exclusion Criteria:
- Not had first cycle of SACT
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | The Christie NHS Foundation Trust | Manchester | United Kingdom |
Sponsors and Collaborators
- Entia Ltd
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Entia Ltd
ClinicalTrials.gov Identifier:
NCT04724005
Other Study ID Numbers:
- 289800
First Posted:
Jan 26, 2021
Last Update Posted:
Mar 22, 2022
Last Verified:
Apr 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms: